Search Within

Samuel Aaron Funt

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (29)
  2. Journal Article (22)
  3. Editorial (1)
Groups
  1. Department of Medicine (52)
  2. Epidemiology and Biostatistics (52)
  3. Genitourinary Oncology Service (52)
  4. Solid Tumor Oncology Division (52)
  5. Weinberg Fellows (52)
  6. Biostatistics Service (47)

More Groups

People
  1. Dean Bajorin (48)
  2. Jonathan Rosenberg (36)
  3. Gopakumar Iyer (34)
  4. Hikmat Al-Ahmadie (28)
  5. Irina Ostrovnaya (27)
  6. Min Yuen Teo (27)

More People

Years
  1. 2025 (1)
  2. 2024 (8)
  3. 2023 (3)
  4. 2022 (7)
  5. 2021 (11)
  6. 2020 (7)

More Years

Publications
  1. Journal of Clinical Oncology (33)
  2. Annals of Oncology (2)
  3. European Urology (2)
  4. JCO Precision Oncology (2)
  5. Annals of Surgery (1)
  6. Annals of Thoracic Surgery (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (35)
  2. Elsevier Science, Inc. (3)
  3. Nature Publishing Group (3)
  4. Oxford University Press (3)
  5. Lippincott Williams & Wilkins (2)
  6. Wiley Blackwell (2)

More Publishers

Results (52)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma
    Journal Article

    Teo, M. Y.; Mota, J. M.; Whiting, K. A.; Li, H. A.; Funt, S. A.; Lee, C. H.; Solit, D. B.; Al-Ahmadie, H.; Milowsky, M. I.; Balar, A. V.; more...
    European Urology (2020)

    Fulltext@MSK | Save
  • Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC)
    Meeting Abstract

    Teo, M. Y.; Whiting, K.; Mota, J. M.; Li, H.; Regazzi, A. M.; Solit, D. B.; Aggen, D. H.; Lee, C. H.; Funt, S. A.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Characterization of tumor mutational landscape in smokers and nonsmokers with urothelial carcinoma
    Meeting Abstract

    Walasek, A.; Almassi, N.; Teo, M. Y.; Funt, S.; Schultz, N.; Dalbagni, G.; Hu, W.; Al-Ahmadie, H.; Bajorin, D. F.; Rosenberg, J. E.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract
    Meeting Abstract

    Sarfaty, M.; Ostrovnaya, I.; Teo, M. Y.; Iyer, G.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Detailed evaluation of hearing loss (HL) associated with high-dose (HD) carboplatin for salvage treatment of germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Knezevic, A.; Wilson, K.; Bromberg, M.; Budnick, A.; McHugh, D. J.; Larsen, E.; Bajorin, D. F.; Motzer, R. J.; Tonorezos, E. S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer
    Meeting Abstract

    Cha, E. K.; Iyer, G.; Funt, S. A.; Regazzi, A. M.; Francis, J.; Heinemann, M. H.; Ostrovnaya, I.; Dalbagni, G.; Bajorin, D. F.; Bochner, B. H.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Adjuvant chemotherapy with etoposide plus cisplatin for patients with pathologic stage II nonseminomatous germ cell tumors
    Journal Article

    McHugh, D. J.; Funt, S. A.; Silber, D.; Knezevic, A.; Patil, S.; O'Donnell, D.; Tsai, S.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI)
    Meeting Abstract

    Mota, J. M.; Teo, M. Y.; Whiting, K.; Ostrovnaya, I.; Li, H.; Lee, C. H.; Funt, S. A.; Callahan, M. K.; Iyer, G.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J. S.; Patil, S.; Reuter, V. E.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Milowsky, M. I.; Appleman, L. J.; Dorff, T. B.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save